menu
    • menu
    [{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CV7301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"MolGenie","sponsor":"OntoChem","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MolGenie","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"MolGenie \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"MolGenie \/ OntoChem"},{"orgOrder":0,"company":"IgNova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IgNova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"IgNova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IgNova \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CV2CoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"Ethris","sponsor":"DIOSynVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ethris \/ DIOSynVax","highestDevelopmentStatusID":"4","companyTruncated":"Ethris \/ DIOSynVax"},{"orgOrder":0,"company":"Cevec","sponsor":"Rokote Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"FINCoVac 2.1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cevec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cevec \/ Rokote Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Cevec \/ Rokote Laboratories"},{"orgOrder":0,"company":"Ethris","sponsor":"Laureus Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Series B Financing","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Ethris \/ Laureus Capital","highestDevelopmentStatusID":"4","companyTruncated":"Ethris \/ Laureus Capital"},{"orgOrder":0,"company":"CureVac","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"nCoV-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ CEPI"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"DiosCURE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"DIOS-202","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DiosCURE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiosCURE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"DiosCURE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Smartbax","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Smartbax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Smartbax \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Smartbax \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"ProBioGen","sponsor":"DIOSynVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"DIOS-HFVac3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProBioGen \/ DIOSynVax","highestDevelopmentStatusID":"4","companyTruncated":"ProBioGen \/ DIOSynVax"},{"orgOrder":0,"company":"Innovative Molecules","sponsor":"Life Sciences Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"IM-250","moa":"Helicase-primase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovative Molecules","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovative Molecules \/ Life Sciences Partners","highestDevelopmentStatusID":"4","companyTruncated":"Innovative Molecules \/ Life Sciences Partners"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Shingles Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"BioNTech \/ Pfizer Inc"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ProBioGen

                            Germany arrow
                            EPS
                            Not Confirmed

                            ProBioGen

                            Germany arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DIOS-HFVac3

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : DIOSynVax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ProBioGen Partners with DIOSynVax to Manufacture Trivalent Hemorrhagic Fever Vaccine

                            Details : The partnership aims to support the DIOSynVax product DIOS-HFVac3 vaccine for clinical advancement. It is being evaluated for the treatment of viral hemorrhagic fevers.

                            Product Name : DIOS-HFVac3

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 27, 2024

                            Lead Product(s) : DIOS-HFVac3

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : DIOSynVax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Smartbax

                            Germany arrow
                            EPS
                            Not Confirmed

                            Smartbax

                            Germany arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $1.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics

                            Details : The funds will be used to advance smartbax’s small molecule antibiotics through preclinical studies, expand the company’s scientific team to further develop its innovative research platforms and identify novel solutions against multi-drug resistant p...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 23, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $1.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ethris

                            Germany arrow
                            EPS
                            Not Confirmed

                            Ethris

                            Germany arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-Based COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : DIOSynVax

                            Deal Size : $42.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Be...

                            Details : Ethris will design and manufacture the mRNA vaccine candidate containing DIOSynVax’s broadly protective, multi-virus vaccine antigen payload designs. This vaccine approach aims to provide protection from SARS-CoV-2 - the virus which causes COVID-19 dis...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 21, 2022

                            Lead Product(s) : mRNA-Based COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : DIOSynVax

                            Deal Size : $42.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cevec

                            Germany arrow
                            EPS
                            Not Confirmed

                            Cevec

                            Germany arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FINCoVac 2.1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Rokote Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rokote Laboratories Licenses Cevec’s Cap® Ad Technology For Vaccine Manufacturing

                            Details : Under the agreement, CEVEC has granted ROKOTE a non-exclusive rights to use the CAP® Ad platform for the manufacturing of adeno-based vaccines (FINCoVac 2.1) for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV...

                            Product Name : FINCoVac 2.1

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 20, 2022

                            Lead Product(s) : FINCoVac 2.1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Rokote Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BioNTech

                            Germany arrow
                            EPS
                            Not Confirmed

                            BioNTech

                            Germany arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Shingles Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : $425.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

                            Details : The companies will leverage Pfizer's proprietary antigen technology and BioNTech's proprietary mRNA platform to develop mRNA based vaccine for Shingles. Pfizer will have rights to commercialize the vaccine gobally, except Germany, Turkey and certain deve...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : $225.0 million

                            May 01, 2022

                            Lead Product(s) : mRNA-based Shingles Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : $425.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ethris

                            Germany arrow
                            EPS
                            Not Confirmed

                            Ethris

                            Germany arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH47

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Laureus Capital

                            Deal Size : $26.3 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases

                            Details : The proceeds will advance the company’s lead programs ETH47 and ETH42, into clinical studies, further advance its proprietary and differentiated mRNA and lipidoid nanoparticle delivery platforms and increase its manufacturing capabilities.

                            Product Name : ETH47

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 02, 2022

                            Lead Product(s) : ETH47

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Laureus Capital

                            Deal Size : $26.3 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            DiosCURE Therapeutics

                            Germany arrow
                            EPS
                            Not Confirmed

                            DiosCURE Therapeutics

                            Germany arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DIOS-202,DIOS-203

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2

                            Details : Preclinical studies demonstrated that DIOS-202 and DIOS-203 selectively target two distinct epitopes of the SARS-CoV-2 spike protein at once, which largely prevents the emergence of escape mutants.

                            Product Name : DIOS-202

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 01, 2021

                            Lead Product(s) : DIOS-202,DIOS-203

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Innovative Molecules

                            Germany arrow
                            EPS
                            Not Confirmed

                            Innovative Molecules

                            Germany arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IM-250

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Life Sciences Partners

                            Deal Size : $23.7 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Innovative Molecules Raises €20 Million Series A Equity Financing Round

                            Details : The company will use the funds to advance its preclinical product candidate, IM-250, from the current late preclinical stage to a Phase 2 proof-of-concept study. IM-250 is a potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) repli...

                            Product Name : IM-250

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 06, 2021

                            Lead Product(s) : IM-250

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Life Sciences Partners

                            Deal Size : $23.7 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MolGenie

                            Germany arrow
                            EPS
                            Not Confirmed

                            MolGenie

                            Germany arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : OntoChem

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie

                            Details : Anixa and OntoChem were seeking to develop an orally administrable, metabolically stable, non-toxic anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19. Anixa is now working with MolGenie to use the generated compounds and data.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 05, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : OntoChem

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CureVac

                            Germany arrow
                            EPS
                            Not Confirmed

                            CureVac

                            Germany arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CV2CoV

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants ...

                            Details : Preclinical data in rats immunized with CV2CoV in the dose range of 0.5-40µg demonstrated fast onset of strong immune responses already after the first dose.

                            Product Name : CV2CoV

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 13, 2021

                            Lead Product(s) : CV2CoV

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth